This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The 5 Dumbest Things on Wall Street: Oct. 7

Stocks in this article: YHOOMSBACAMEDLHCGGTIVAMR

3. Homecare Hokum

No, no, no Senators. It's not that the nation's biggest home care providers are ripping off Medicare by making more and more and more visits to patients. It's just that they really, really, really care.

Yeah right. And if you believe that, we have a bridge to sell you.

Shares of Amedisys (AMED), LHC Group (LHCG) and Gentiva (GTIV) got slammed early this week after a report released by the Senate Finance committee found the companies were increasing home care, even when patients may not have required extra attention. The incentive to bilk Medicare dollars was reportedly so strong that one company even went so far as to assemble a special crew to maximize the most profitable treatment regimens possible.

That's right. It may have looked like a never-ending stream of nurses looking after your loved ones, but it was really a SWAT team of swindlers ripping off you and me.

"Elderly patients in the Medicare system should not be used as pawns to increase a company's profits," said Senator Max Baucus in a statement. "Especially in these tough economic times, taxpayers simply cannot afford for their dollars to be wasted on unnecessary care."

Darn tooting Max! And you all better pay attention to the man because if there one group that knows how to spend money unnecessarily its Baucus and all his buddies in Congress.

LHC Group has already announced it's agreed to pay $65 million to settle a civil inquiry with the federal government over whether some government-reimbursed patient care was medically necessary. Under the agreement, LHC did not admit any wrongdoing and the company said it still disputes the claims. Same goes for Gentiva and Amedisys, which said it was "disappointed with the committee's conclusions" and that it stands by its "integrity, ethics and patient care practices."

If you ask us, all three companies should quit with the blah, blah, blah and clear their calendars for some very, very, very tough meetings. The Department of Justice is going to be visiting soon and they really, really, really don't want to hear excuses.

And that you can believe.

3 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs